tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2023 Feb 18;10(3)
fad091.
doi: 10.1093/ofid/ofad091. eCollection 2023 Mar.
Use of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Tests by US Infectious Disease Physicians: Results of an Emerging Infections Network Survey, March 2022
Adi V Gundlapalli[SUP] 1 [/SUP], Susan E Beekmann[SUP] 2 [/SUP], Jefferson M Jones[SUP] 1 [/SUP], Natalie J Thornburg[SUP] 1 [/SUP], Kristie E N Clarke[SUP] 1 [/SUP], Timothy M Uyeki[SUP] 1 [/SUP], Panayampalli S Satheshkumar[SUP] 1 [/SUP], Darin S Carroll[SUP] 1 [/SUP], Ian D Plumb[SUP] 1 [/SUP], Melissa Briggs-Hagen[SUP] 1 [/SUP], Scott Santibañez[SUP] 1 [/SUP], Corinne David-Ferdon[SUP] 1 [/SUP], Philip M Polgreen[SUP] 2 [/SUP], L Clifford McDonald[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests have had limited recommended clinical application during the coronavirus disease 2019 (COVID-19) pandemic. To inform clinical practice, an understanding is needed of current perspectives of United States-based infectious disease (ID) physicians on the use, interpretation, and need for SARS-CoV-2 antibody tests.
Methods: In March 2022, members of the Emerging Infections Network (EIN), a national network of practicing ID physicians, were surveyed on types of SARS-CoV-2 antibody assays ordered, interpretation of test results, and clinical scenarios for which antibody tests were considered.
Results: Of 1867 active EIN members, 747 (40%) responded. Among the 583 who managed or consulted on COVID-19 patients, a majority (434/583 [75%]) had ordered SARS-CoV-2 antibody tests and were comfortable interpreting positive (452/578 [78%]) and negative (405/562 [72%]) results. Antibody tests were used for diagnosing post-COVID-19 conditions (61%), identifying prior SARS-CoV-2 infection (60%), and differentiating prior infection and response to COVID-19 vaccination (37%). Less than a third of respondents had used antibody tests to assess need for additional vaccines or risk stratification. Lack of sufficient evidence for use and nonstandardized assays were among the most common barriers for ordering tests. Respondents indicated that statements from professional societies and government agencies would influence their decision to order SARS-CoV-2 antibody tests for clinical decision making.
Conclusions: Practicing ID physicians are using SARS-CoV-2 antibody tests, and there is an unmet need for clarifying the appropriate use of these tests in clinical practice. Professional societies and US government agencies can support clinicians in the community through the creation of appropriate guidance.
Keywords: COVID-19; SARS-CoV-2; antibody tests; serology; utilization.
. 2023 Feb 18;10(3)
fad091.doi: 10.1093/ofid/ofad091. eCollection 2023 Mar.
Use of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Tests by US Infectious Disease Physicians: Results of an Emerging Infections Network Survey, March 2022
Adi V Gundlapalli[SUP] 1 [/SUP], Susan E Beekmann[SUP] 2 [/SUP], Jefferson M Jones[SUP] 1 [/SUP], Natalie J Thornburg[SUP] 1 [/SUP], Kristie E N Clarke[SUP] 1 [/SUP], Timothy M Uyeki[SUP] 1 [/SUP], Panayampalli S Satheshkumar[SUP] 1 [/SUP], Darin S Carroll[SUP] 1 [/SUP], Ian D Plumb[SUP] 1 [/SUP], Melissa Briggs-Hagen[SUP] 1 [/SUP], Scott Santibañez[SUP] 1 [/SUP], Corinne David-Ferdon[SUP] 1 [/SUP], Philip M Polgreen[SUP] 2 [/SUP], L Clifford McDonald[SUP] 1 [/SUP]
Affiliations
- PMID: 36949879
- PMCID: PMC10026543 (available on 2024-02-18)
- DOI: 10.1093/ofid/ofad091
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests have had limited recommended clinical application during the coronavirus disease 2019 (COVID-19) pandemic. To inform clinical practice, an understanding is needed of current perspectives of United States-based infectious disease (ID) physicians on the use, interpretation, and need for SARS-CoV-2 antibody tests.
Methods: In March 2022, members of the Emerging Infections Network (EIN), a national network of practicing ID physicians, were surveyed on types of SARS-CoV-2 antibody assays ordered, interpretation of test results, and clinical scenarios for which antibody tests were considered.
Results: Of 1867 active EIN members, 747 (40%) responded. Among the 583 who managed or consulted on COVID-19 patients, a majority (434/583 [75%]) had ordered SARS-CoV-2 antibody tests and were comfortable interpreting positive (452/578 [78%]) and negative (405/562 [72%]) results. Antibody tests were used for diagnosing post-COVID-19 conditions (61%), identifying prior SARS-CoV-2 infection (60%), and differentiating prior infection and response to COVID-19 vaccination (37%). Less than a third of respondents had used antibody tests to assess need for additional vaccines or risk stratification. Lack of sufficient evidence for use and nonstandardized assays were among the most common barriers for ordering tests. Respondents indicated that statements from professional societies and government agencies would influence their decision to order SARS-CoV-2 antibody tests for clinical decision making.
Conclusions: Practicing ID physicians are using SARS-CoV-2 antibody tests, and there is an unmet need for clarifying the appropriate use of these tests in clinical practice. Professional societies and US government agencies can support clinicians in the community through the creation of appropriate guidance.
Keywords: COVID-19; SARS-CoV-2; antibody tests; serology; utilization.